Shopping Cart 0
Cart Subtotal
USD 0

Hepatitis B-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Hepatitis B-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B-Pipeline Review, H1 2017, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 8, 27, 26, 4, 56, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 6

Hepatitis B-Overview 7

Hepatitis B-Therapeutics Development 8

Hepatitis B-Therapeutics Assessment 27

Hepatitis B-Companies Involved in Therapeutics Development 37

Hepatitis B-Drug Profiles 79

Hepatitis B-Dormant Projects 317

Hepatitis B-Discontinued Products 324

Hepatitis B-Product Development Milestones 325

Appendix 334


List Of Figure

List of Figures

Number of Products under Development for Hepatitis B, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Hepatitis B, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatitis B-Pipeline by Abivax SA, H1 2017

Hepatitis B-Pipeline by AiCuris GmbH & Co KG, H1 2017

Hepatitis B-Pipeline by AIMM Therapeutics BV, H1 2017

Hepatitis B-Pipeline by Akshaya Bio Inc, H1 2017

Hepatitis B-Pipeline by Alnylam Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by Altimmune Inc, H1 2017

Hepatitis B-Pipeline by Altravax Inc, H1 2017

Hepatitis B-Pipeline by Amarna Therapeutics BV, H1 2017

Hepatitis B-Pipeline by Arbutus Biopharma Corp, H1 2017

Hepatitis B-Pipeline by Arcturus Therapeutics Inc, H1 2017

Hepatitis B-Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by Assembly Biosciences Inc, H1 2017

Hepatitis B-Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017

Hepatitis B-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Hepatitis B-Pipeline by Benitec Biopharma Ltd, H1 2017

Hepatitis B-Pipeline by Biological E Ltd, H1 2017

Hepatitis B-Pipeline by BioStar Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by Bolder Biotechnology Inc, H1 2017

Hepatitis B-Pipeline by BrightGene Bio-Medical Technology Co Ltd, H1 2017

Hepatitis B-Pipeline by Bukwang Pharm Co Ltd, H1 2017

Hepatitis B-Pipeline by CaroGen Corp, H1 2017

Hepatitis B-Pipeline by Celltrion Inc, H1 2017

Hepatitis B-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Hepatitis B-Pipeline by Chromis Therapeutics Inc, H1 2017

Hepatitis B-Pipeline by Cocrystal Pharma Inc, H1 2017

Hepatitis B-Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by CyTuVax BV, H1 2017

Hepatitis B-Pipeline by Dicerna Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Hepatitis B-Pipeline by Dynavax Technologies Corp, H1 2017

Hepatitis B-Pipeline by Ensemble Therapeutics Corp, H1 2017

Hepatitis B-Pipeline by Enyo Pharma SA, H1 2017

Hepatitis B-Pipeline by eTheRNA Immunotherapies NV, H1 2017

Hepatitis B-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hepatitis B-Pipeline by GeneCure LLC, H1 2017

Hepatitis B-Pipeline by GeoVax Labs Inc, H1 2017

Hepatitis B-Pipeline by Gilead Sciences Inc, H1 2017

Hepatitis B-Pipeline by GlaxoSmithKline Plc, H1 2017

Hepatitis B-Pipeline by Green Cross Corp, H1 2017

Hepatitis B-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Hepatitis B-Pipeline by Humabs BioMed SA, H1 2017

Hepatitis B-Pipeline by Huons Co Ltd, H1 2017

Hepatitis B-Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Hepatitis B-Pipeline by Immunotope Inc, H1 2017

Hepatitis B-Pipeline by Indian Immunologicals Ltd, H1 2017

Hepatitis B-Pipeline by Intellia Therapeutics Inc, H1 2017

Hepatitis B-Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by ISA Pharmaceuticals BV, H1 2017

Hepatitis B-Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Hepatitis B-Pipeline by Johnson & Johnson, H1 2017

Hepatitis B-Pipeline by Kineta Inc, H1 2017

Hepatitis B-Pipeline by Leukocare AG, H1 2017

Hepatitis B-Pipeline by LG Chem, Ltd., H1 2017

Hepatitis B-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by Medivir AB, H1 2017

Hepatitis B-Pipeline by Mucosis BV, H1 2017

Hepatitis B-Pipeline by MultiCell Technologies Inc, H1 2017

Hepatitis B-Pipeline by Oncolys BioPharma Inc, H1 2017

Hepatitis B-Pipeline by Panacea Biotec Ltd, H1 2017

Hepatitis B-Pipeline by Pfenex Inc, H1 2017

Hepatitis B-Pipeline by PharmaEssentia Corp, H1 2017

Hepatitis B-Pipeline by Profarma, H1 2017

Hepatitis B-Pipeline by Profectus BioSciences Inc, H1 2017

Hepatitis B-Pipeline by Replicor Inc, H1 2017

Hepatitis B-Pipeline by Rodos BioTarget GmbH, H1 2017

Hepatitis B-Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Hepatitis B-Pipeline by Sanofi, H1 2017

Hepatitis B-Pipeline by Sanofi Pasteur SA, H1 2017

Hepatitis B-Pipeline by Scynexis Inc, H1 2017

Hepatitis B-Pipeline by Shantha Biotechnics Ltd, H1 2017

Hepatitis B-Pipeline by Sinovac Biotech Ltd, H1 2017

Hepatitis B-Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017

Hepatitis B-Pipeline by TCM Biotech International Corp, H1 2017

Hepatitis B-Pipeline by Theravectys SA, H1 2017

Hepatitis B-Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017

Hepatitis B-Pipeline by Tomegavax Inc, H1 2017

Hepatitis B-Pipeline by Transgene SA, H1 2017

Hepatitis B-Pipeline by Vaxine Pty Ltd, H1 2017

Hepatitis B-Pipeline by VBI Vaccines Inc, H1 2017

Hepatitis B-Pipeline by Vical Inc, H1 2017

Hepatitis B-Pipeline by ViroStatics srl, H1 2017

patitis B-Pipeline by VLP Biotech Inc, H1 2017

Hepatitis B-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Hepatitis B-Dormant Projects, H1 2017

Hepatitis B-Dormant Projects, H1 2017 (Contd..1), H1 2017

Hepatitis B-Dormant Projects, H1 2017 (Contd..2), H1 2017

Hepatitis B-Dormant Projects, H1 2017 (Contd..3), H1 2017

Hepatitis B-Dormant Projects, H1 2017 (Contd..4), H1 2017

Hepatitis B-Dormant Projects, H1 2017 (Contd..5), H1 2017

Hepatitis B-Dormant Projects, H1 2017 (Contd..6), H1 2017

Hepatitis B-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Abivax SA, AiCuris GmbH & Co KG, AIMM Therapeutics BV, Akshaya Bio Inc, Alnylam Pharmaceuticals Inc, Altimmune Inc, Altravax Inc, Amarna Therapeutics BV, Arbutus Biopharma Corp, Arcturus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Assembly Biosciences Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beijing Minhai Biotechnology Co Ltd, Benitec Biopharma Ltd, Biological E Ltd, BioStar Pharmaceuticals Inc, Bolder Biotechnology Inc, BrightGene Bio-Medical Technology Co Ltd, Bukwang Pharm Co Ltd, CaroGen Corp, Celltrion Inc, Chong Kun Dang Pharmaceutical Corp, Chromis Therapeutics Inc, Cocrystal Pharma Inc, ContraVir Pharmaceuticals Inc, CyTuVax BV, Dicerna Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Dynavax Technologies Corp, Ensemble Therapeutics Corp, Enyo Pharma SA, eTheRNA Immunotherapies NV, F. Hoffmann-La Roche Ltd, GeneCure LLC, GeoVax Labs Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Green Cross Corp, Hanmi Pharmaceuticals Co Ltd, Humabs BioMed SA, Huons Co Ltd, Ildong Pharmaceutical Co Ltd, Immunotope Inc, Indian Immunologicals Ltd, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, ISA Pharmaceuticals BV, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Johnson & Johnson, Kineta Inc, Leukocare AG, LG Chem, Ltd., Ligand Pharmaceuticals Inc, Medivir AB, Mucosis BV, MultiCell Technologies Inc, Oncolys BioPharma Inc, Panacea Biotec Ltd, Pfenex Inc, PharmaEssentia Corp, Profarma, Profectus BioSciences Inc, Replicor Inc, Rodos BioTarget GmbH, Samjin Pharmaceutical Co Ltd, Sanofi, Sanofi Pasteur SA, Scynexis Inc, Shantha Biotechnics Ltd, Sinovac Biotech Ltd, Spring Bank Pharmaceuticals Inc, TCM Biotech International Corp, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Tomegavax Inc, Transgene SA, Vaxine Pty Ltd, VBI Vaccines Inc, Vical Inc, ViroStatics srl, VLP Biotech Inc, Zydus Cadila Healthcare Ltd